Peptide-mediated	JJ
inhibition	NN
of	IN
mitogen-activated	JJ
protein	NN
kinase-activated	JJ
protein	NN
kinase-2	NN
ameliorates	VBZ
bleomycin-induced	JJ
pulmonary	JJ
fibrosis	NN
.	.

Mitogen-activated-protein-kinase-activated-protein-kinase-2	NN
(	(
MAPKAPK2	NN
,	,
or	CC
MK2	NN
)	)
,	,
a	DT
serine/threonine	NN
kinase	NN
downstream	RB
of	IN
p38	NN
mitogen-activated	JJ
protein	NN
kinase	NN
,	,
has	VBZ
been	VBN
implicated	VBN
in	IN
inflammation	NN
and	CC
fibrosis	NN
.	.

Compared	VBN
with	IN
pathologically	RB
normal	JJ
lung	NN
tissue	NN
,	,
significantly	RB
higher	JJR
concentrations	NNS
of	IN
activated	VBN
MK2	NN
are	VBP
evident	JJ
in	IN
lung	NN
biopsies	NNS
of	IN
patients	NNS
with	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
.	.

Expression	NN
is	VBZ
localized	JJ
to	TO
fibroblasts	NNS
and	CC
epithelial	JJ
cells	NNS
.	.

In	IN
the	DT
murine	JJ
bleomycin	NN
model	NN
of	IN
pulmonary	JJ
fibrosis	NN
,	,
we	PRP
observed	VBD
robust	JJ
,	,
activated	VBN
MK2	NN
expression	NN
on	IN
Day	NN
7	CD
(	(
prefibrotic	JJ
stage	NN
)	)
and	CC
Day	NN
14	CD
(	(
postfibrotic	JJ
stage	NN
)	)
.	.

To	TO
determine	VB
the	DT
effects	NNS
of	IN
MK2	NN
inhibition	NN
during	IN
the	DT
postinflammatory/prefibrotic	JJ
and	CC
postfibrotic	JJ
stages	NNS
,	,
C57BL/6	NN
mice	NNS
received	VBD
intratracheal	JJ
bleomycin	NN
instillation	NN
(	(
0.025	CD
U	NN
;	:
Day	NN
0	CD
)	)
,	,
followed	VBN
by	IN
PBS	NNP
or	CC
the	DT
MK2	NN
inhibitor	NN
(	(
MK2i	NN
;	:
37.5	CD
g/kg	NN
)	)
,	,
administered	VBN
via	IN
either	CC
local	JJ
(	(
nebulized	JJ
)	)
or	CC
systemic	JJ
(	(
intraperitoneal	JJ
)	)
routes	NNS
.	.

MK2i	NN
or	CC
PBS	NNP
was	VBD
dosed	VBN
daily	RB
for	IN
14	CD
days	NNS
subsequent	JJ
to	TO
bleomycin	NN
injury	NN
,	,
beginning	VBG
on	IN
either	CC
Day	NN
7	CD
or	CC
Day	NN
14	CD
.	.

Regardless	RB
of	IN
mode	NN
of	IN
administration	NN
or	CC
stage	NN
of	IN
intervention	NN
,	,
MK2i	NN
significantly	RB
abrogated	VBD
collagen	NN
deposition	NN
,	,
myofibroblast	NN
differentiation	NN
and	CC
activated	VBN
MK2	NN
expression	NN
.	.

MK2i	NN
also	RB
decreased	VBD
circulating	VBG
TNF-a	NN
and	CC
IL-6	NN
concentrations	NNS
,	,
and	CC
modulated	VBD
the	DT
local	JJ
mRNA	NN
expression	NN
of	IN
profibrotic	JJ
cytokine	NN
il-1b	NN
,	,
matrix-related	JJ
genes	NNS
col1a2	NN
,	,
col3a1	NN
,	,
and	CC
lox	NN
,	,
and	CC
transforming-growth-factor-b	JJ
family	NN
members	NNS
,	,
including	VBG
smad3	NN
,	,
serpine1	NN
(	(
pai1	NN
)	)
,	,
and	CC
smad6/7	NN
.	.

In	FW
vitro	FW
,	,
MK2i	NN
dose-dependently	RB
attenuated	VBD
total	JJ
MK2	NN
,	,
myofibroblast	NN
differentiation	NN
,	,
the	DT
secretion	NN
of	IN
collagen	NN
Type	NN
I	CD
,	,
fibronectin	NN
,	,
and	CC
the	DT
activation	NN
of	IN
focal-adhesion-kinase	NN
,	,
whereas	IN
activated	VBN
MK2	NN
was	VBD
attenuated	VBN
at	IN
optimal	JJ
doses	NNS
.	.

The	DT
peptide-mediated	JJ
inhibition	NN
of	IN
MK2	NN
affects	VBZ
both	CC
inflammatory	JJ
and	CC
fibrotic	JJ
responses	NNS
,	,
and	CC
thus	RB
may	MD
offer	VB
a	DT
promising	JJ
therapeutic	JJ
target	NN
for	IN
IPF	NN
.	.

